IRIS
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.352
AS - Asia 49
SA - Sud America 12
NA - Nord America 1
Totale 2.414
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.351
CN - Cina 36
BR - Brasile 10
VN - Vietnam 7
SG - Singapore 5
AR - Argentina 1
BD - Bangladesh 1
CO - Colombia 1
UA - Ucraina 1
US - Stati Uniti d'America 1
Totale 2.414
Salva come PNG Salva come JPEG
Città #
Genova 1.002
Genoa 945
Rapallo 225
Vado Ligure 169
Beijing 19
Bordighera 10
Hanoi 3
Curitiba 2
Singapore 2
Araruama 1
Campina Grande do Sul 1
Ho Chi Minh City 1
Hortolândia 1
Itu 1
Lorena 1
Macapá 1
Milltown 1
Nha Trang 1
Pouso Alegre 1
Punta Alta 1
Santa Marta 1
Sátiro Dias 1
Ternopil 1
Thái Bình 1
Totale 2.392
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 212
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 182
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 179
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 178
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 168
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 160
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 159
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 155
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 149
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 140
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 140
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 132
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 107
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 107
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab 92
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 88
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 61
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 34
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma 32
Totale 2.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.678
article - articoli 8.678
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021138 0 0 0 0 20 8 5 19 13 31 12 30
2021/2022206 5 2 20 29 15 20 11 30 16 16 11 31
2022/2023277 26 27 4 26 54 29 1 11 36 13 45 5
2023/2024249 3 23 4 22 14 61 30 48 6 8 15 15
2024/2025584 16 31 17 34 38 55 69 143 24 22 66 69
2025/2026312 128 25 49 105 5 0 0 0 0 0 0 0
Totale 2.475